FDA Inspection 1037415 — Zhejiang Hisoar Chuannan Pharmaceutical Co. Ltd.
The FDA completed an inspection of Zhejiang Hisoar Chuannan Pharmaceutical Co. Ltd. on Nov 2, 2017 in Taizhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 2, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Taizhou (China)